Innoviva Inc

Most Recent

  • uploads///NKTR
    Company & Industry Overviews

    What Does Nektar Therapeutics’ Valuation Trend Indicate?

    Under its immunology program, Nektar Therapeutics (NKTR) is developing NKTR-358 in collaboration with Eli Lilly and Company (LLY).

    By Kenneth Smith
  • uploads///Pulmicort revenues
    Company & Industry Overviews

    AstraZeneca’s Respiratory Drugs: Pulmicort, Daliresp, and Tudorza

    In 3Q17, Tudorza generated revenues of $37.0 million, which reflected an ~21.0% decline on a YoY basis.

    By Daniel Collins
  • uploads///Chart
    Company & Industry Overviews

    Ionis Pharmaceuticals’ Valuation Compared to Its Peers

    According to March 20, 2017, data, Ionis stock has risen 4.1% over the last 12 months.

    By Mike Benson
  • uploads///Chart
    Company & Industry Overviews

    How Ionis Pharmaceuticals’ Valuation Compares to Its Peers

    Ionis’s stock value has fallen 42% over the last 12 months. Analysts estimate that the stock has the potential to return ~27% over the next 12 months.

    By Mike Benson
    • CONNECT with Market Realist
    • Link to Facebook
    • Link to Twitter
    • Link to Instagram
    • Link to Email Subscribe
    Market Realist Logo

    © Copyright 2021 Market Realist. Market Realist is a registered trademark. All Rights Reserved. People may receive compensation for some links to products and services on this website. Offers may be subject to change without notice.